CMV Drug Resistance Detection Assay

Cytomegalovirus (CMV) remains a significant challenge for immunocompromised patients, especially transplant recipients, due to the rise of drug-resistant strains that limit treatment options. This project aims to develop and validate in-house molecular assays to accurately and efficiently detect CMV drug resistance mutations. Initially, the assays will use Sanger sequencing to detect known resistance mutations precisely, with plans to expand to next-generation sequencing (NGS) for comprehensive profiling, including new mutations. These assays will give clinicians actionable information, supporting personalized antiviral treatment and better patient outcomes. Besides the clinical benefits, the project strengthens local capacity in infectious disease diagnostics, promotes antimicrobial stewardship, and positions our institution as a leader in innovative, translational research. By advancing precision medicine, this initiative will change how CMV infections are diagnosed and treated regionally.

The Genomic Medicine Center of Excellence.